Document is current
Any future updates will be listed below
-
Authors
Mestre-Ferrandiz, Jorge https://orcid.org/0000-0003-0529-1321
Navarro-Compán, Victoria https://orcid.org/0000-0002-4527-852X
Ivanova-Markova, Yoana
González-Domínguez, Almudena
Maratia, Stefano
-
Funding
Funding for this research was provided by:
UCB Pharma Spain
- License Information
-
More Information
Article History
Received: 11 June 2025
Accepted: 20 October 2025
First Online: 6 November 2025
Declarations
:
: Jorge Mestre-Ferrándiz: Consultant fees from UCB; Victoria Navarro-Compán has received consulting fees, research or institutional support and educational grants from: AbbVie, Alfasigma, Bristol Myers Squibb, Eli Lilly, Fresenius Kabi, Galapagos, Janssen, Johnson & Johnson, Moonlake, MSD, Novartis, Pfizer, Roche, UCB; Yoana Ivanova-Markova and Almudena González-Dominguez: Employees of Weber; Stefano Maratia: Employee of UCB. Almudena González-Domínguez changed affiliation during the completion of this manuscript. Her current affiliation is Lead, Health Economics & Market Access, Theorema4h, Madrid, Spain.
: Our study did not require approval from any ethics committee. Applying the Helsinki Declaration not necessary, because the efficacy data we used were from previously published studies where confirmation of compliance with the Declaration of Helsinki and Good Clinical Practice had been performed.
